clinical trial · NCT05586971
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
LG Chem·phase3·completed·n = 2,202
GoutHyperuricemiaGout FlareTophiTigulixostatAllopurinolPlacebo
brief summary
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
started
Mar 30, 2023
primary completion
May 6, 2025
completion
May 6, 2025
last updated
Jul 22, 2025
official title
A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol